Senno Therapeutics Accelerates Development of Cell Therapy Using iPS Cell-Derived Hepatoblasts
NQ Score
80/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Senno Therapeutics, aiming to resolve unmet medical needs in liver failure, raised funds totaling 750 million yen to accelerate the development of 'SEN-001', a cell therapy using allogeneic iPS cell-derived hepatoblasts.